ETERN Therapeutics
PrivateLast Round
Series B
Extension
Jun 26, 2026
Total Funding Raised
$13.4M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
ETERN Therapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series B Extension round in June 2026.
ETERN Therapeutics is a biotechnology company that develops novel small molecule drugs targeting undruggable proteins using a proprietary liquid-liquid phase separation (LLPS) technology platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ETERN Therapeutics Comparables
Compare ETERN Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nereid Therapeutics | 84% | |
| Transition Bio | 83% | |
| Dewpoint Therapeutics | 79% |
For institutional investors. Book with your work email.
ETERN Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jun 26, 2026 | ||||
| Series B Extension | Apr 1, 2024 | ||||
| Series B | Sep 1, 2021 | ||||
| Series A | Apr 9, 2020 | ||||
| Angel | Dec 31, 2018 | ||||
Angel | Dec 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ETERN Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hillhouse Investment | Series B |
| TF Capital | Series B, Series A |
| Morningside Ventures | Series B |
| Wuxi High-tech Zone Venture Capital Holding Group | Series B Extension |
| BOHE Angel Fund | Series A |
| Wuxi Capital Group Co.,Ltd | Series B Extension |
| Apricot Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 91% MoM, reaching 4.6K.
- Jun 26, 2026
Led by AstraZeneca-CICC Healthcare Industrial Fund and Wuxi Capital Group.
For institutional investors. Book with your work email.
ETERN Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ETERN Therapeutics's valuation, stock price, and market status.
Is ETERN Therapeutics a public or private company?
ETERN Therapeutics is a private company.
What is the current stock price of ETERN Therapeutics?
ETERN Therapeutics is a private company, so its shares have no public market price. Caplight tracks ETERN Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ETERN Therapeutics worth (valuation)?
Valuation information for ETERN Therapeutics is not publicly available.
Can I buy ETERN Therapeutics stock?
ETERN Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ETERN Therapeutics's last funding round?
ETERN Therapeutics's most recent funding round was Series B Extension on June 26, 2026.
Who are the main investors in ETERN Therapeutics?
Key investors in ETERN Therapeutics include Hillhouse Investment, TF Capital, Wuxi Capital Group Co.,Ltd, Apricot Capital.
Will ETERN Therapeutics IPO soon?
No public IPO plans have been announced for ETERN Therapeutics.
How can I track ETERN Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in ETERN Therapeutics's shares on secondary markets.